These findings identify PLXNA2 as a candidate marker of expansion state and provide a lineage-based framework for discovering tumor-initiating programs in LUAD.
Abstract
Introduction Only a subset of epithelial cells can initiate progressive lung adenocarcinoma (LUAD), yet the founder cell states that confer this competence remain poorly defined. Methods We established a barcoded KrasG12D, Trp53 loss mouse LUAD organoid model that couples 15-nucleotide lineage tracing with single-cell RNA sequencing (scRNA-seq) before and after syngeneic transplantation. Candidate markers for expansion states were further evaluated using wild-type lung organoid, spatial transcriptomics, and independent human scRNA-seq datasets. Results Barcoded organoids generated LUAD-like tumors. Paired barcode recovery identified expanded, diminished and failed lineages and showed that expanded lineages were enriched for surfaceome genes associated with stemness. Among candidate surface markers, Plxna2 showed the strongest enrichment in baseline organoid cells that expanded after transplantation and marked cells with stronger stemness features. These cells underwent stage-specific reprogramming, with early EMT and inflammatory adaptation followed by late metabolic and MYC programs rebound within an immunosuppressive microenvironment. Wild-type lung organoid analysis showed that Plxna2 marks an alveolar remodeling state sharing expansion signature. Spatial transcriptomics placed Plxna2high tumor epithelial cells in EMT-rich and stromal-interface niches. Human LUAD scRNA-seq cohorts further showed enrichment of PLXNA2high malignant cells within expansion and stemness states. Discussion These findings identify PLXNA2 as a candidate marker of expansion state and provide a lineage-based framework for discovering tumor-initiating programs in LUAD.
A clonal-resolution view of fetal liver HSC heterogeneity is provided, enhancing the understanding of HSC diversity across different developmental stages and suggesting a specific coupling relationship between transcriptional persistence and lineage bias.
Man Zhang, Yan-Li Ni, Di Liu et al.· Zoological Research· 0 citations
These findings establish NF1 as a critical constraint on HPV-associated epithelial evolution and provide a time-compressed organoid model of cervical carcinogenesis, offering proof-of-concept for therapeutic RAS pathway interception via NF1 restoration.
Bai Hu, Liang Chen, Ren-Jie Wang et al.· Cancer Research· 0 citations
Understanding the molecular underpinnings of stem cell differentiation is pivotal for generating appropriate cell types in cell-based therapies. Differentiation of human pluripotent stem cells (PSC) into corneal limbal stem cells offers a promising avenue to regenerate the corneal epithelium. However, current different...
J. Arts, D. L. Cunha, S. Harjuntausta et al.· bioRxiv· 0 citations
Summary Protein C receptor (PROCR) marks a rare population of mammary epithelial cells with stem-like properties, but their low abundance has hindered characterization of their functional diversity and regulatory programs. Here, we integrate targeted enrichment with single-cell transcriptomic and chromatin accessibilit...
Koon-Kiu Yan, Erin A. Nekritz, Zhen Xie et al.· iScience· 0 citations
Human pluripotent stem cells serve as a vital model for studying early human lineage specification, yet conventional assessments relying on endpoint canonical markers of the three germ layers may overlook transient intermediate states and broader cellular programs. Here we combined directed differentiation of human ind...
Alice C. Borges, Mariana A. Branco, João P. Cotovio et al.· bioRxiv· 0 citations
Disseminated cancer cells (DCC) in non-metastatic carcinoma patient bone marrow (BM) are predictive of metastasis. Those detected by epithelial cytokeratin or EpCAM expression have poorly-characterized transcription profiles due to their extreme rarity: 1∼2 cells per 2x 106 BM cells in every third non-metastatic patien...
Huiqin Körkel-Qu, Elia Raya, M. Gužvić et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.